Published in Clin Imaging on November 30, 2016
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Cancer statistics, 2006. CA Cancer J Clin (2006) 30.71
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med (2015) 4.78
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol (2011) 4.37
Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A (2008) 4.14
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol (2011) 2.44
Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. PLoS One (2011) 2.35
Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations. Radiology (2013) 2.21
Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur J Radiol (2009) 1.92
Radiogenomic analysis of breast cancer using MRI: a preliminary study to define the landscape. AJR Am J Roentgenol (2012) 1.82
A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol (2012) 1.48
Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma. J Vasc Interv Radiol (2007) 1.42
Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res (2013) 1.36
Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol (2013) 1.31
Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. Radiology (2013) 1.21
CT features of peripheral pulmonary carcinoid tumors. AJR Am J Roentgenol (2011) 1.20
Illuminating radiogenomic characteristics of glioblastoma multiforme through integration of MR imaging, messenger RNA expression, and DNA copy number variation. Radiology (2013) 1.13
Epidermal growth factor receptor gene mutation and computed tomographic findings in peripheral pulmonary adenocarcinoma. J Thorac Oncol (2006) 1.09
Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features? J Thorac Oncol (2010) 1.08
Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements? Lung Cancer (2014) 1.05
CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer. Eur Radiol (2015) 0.99
ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization. Radiology (2014) 0.97
Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer. Cancer (2008) 0.96
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Cancer (2014) 0.95
Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation. Radiology (2015) 0.93
NF-κB protein expression associates with (18)F-FDG PET tumor uptake in non-small cell lung cancer: a radiogenomics validation study to understand tumor metabolism. Lung Cancer (2013) 0.90
Correlation between EGFR mutation status and computed tomography features in patients with advanced pulmonary adenocarcinoma. J Thorac Imaging (2014) 0.86
Approach to ground-glass opacification of the lung. Semin Ultrasound CT MR (2002) 0.82